Unknown

Dataset Information

Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer.


ABSTRACT: Androgen receptor (AR) inhibition is standard of care for advanced prostate cancer (PC). However, efficacy is limited by progression to castration-resistant PC (CRPC), usually due to AR re-activation via mechanisms that include AR amplification and structural rearrangement. These two classes of AR alterations often co-occur in CRPC tumors, but it is unclear whether this reflects intercellular or intracellular heterogeneity of AR. Resolving this is important for developing new therapies and predictive biomarkers. Here, we analyzed 41 CRPC tumors and 6 patient-derived xenografts (PDXs) using linked-read DNA-sequencing, and identified 7 tumors that developed complex, multiply-rearranged AR gene structures in conjunction with very high AR copy number. Analysi

SUBMITTER: Zivanovic A 

PROVIDER: S-EPMC10448862 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature